Physician profile
Andrew Bausch
NPI 1902882129
$5,193.72
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,057 · 2020: $178 · 2021: $361 · 2022: $499 · 2023: $97.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $97.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $97.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,270.31 | 2019-2022 | |
| Glaukos Corporation | $1,000.00 | 2019 | |
| Allergan, INC. | $401.24 | 2019-2021 | |
| Alcon Vision LLC | $376.05 | 2019-2023 | Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $239.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $150.77 | 2019-2023 | |
| New World Medical,INC. | $140.54 | 2019 | |
| Sight Sciences, INC. | $131.23 | 2020-2023 | Omni Surgical System |
| Abbvie INC. | $116.03 | 2022-2023 | Durysta |
| Kala Pharmaceuticals, INC. | $83.85 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $81.57 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $78.30 | 2022 | |
| Oyster Point Pharma, INC. | $44.69 | 2022 | |
| Rayner Intraocular Lenses Limited | $37.34 | 2022 | |
| Rxsight INC | $19.32 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $12.28 | 2019 | |
| Ocular Therapeutix, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bausch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.